Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals

Experimental and Therapeutic Medicine

Volumn 7, Issue 2, 2014, Pages 393-396

  Zhang, Mei ^a   Di, Xiaohui ^a   Xu, Lin ^a   Xu, Juan ^a   Yang, Yongge ^a   Jiang, Nan ^a   Song, Lixue ^a   Xu, Xueting ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Febuxostat; Pharmacodynamics; Pharmacokinetics; Serum uric acid

Indexed keywords

FEBUXOSTAT;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL;

EID: 84890449910     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1414     Document Type: Article

References (11)

1. Liu B, Wang T, Zhao H, Yue W, Yu H, Liu C, Yin J, Jia R and Nie H: The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health 11: 832, 2011.
2. Nyhan WL: Disorders of purine and pyrimidine metabolism. Mol Genet Metab 86(1-2): 25-33, 2005.
3. Guidelines for the research of chemical drug and clinical pharmacokinetics. China Food and Drug Administration 2005 (In Chinese).
4. Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang SY, Chen PY, Chen HC, Chang CT and Huang WL: Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 65: 133-140.
5. Reinders MK and Jansen TL: Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 5: 7-18, 2010.
6. Wallace KL, Riedel AA, Joseph-Ridge N and Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31: 1582-1587, 2004.
7. Bruce SP: Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 40: 2187-2194, 2006.
8. Szasz T, Davis RP, Garver HS, Burnett RJ, Fink GD and Watts SW: Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. PloS One 8: e56046.
9. Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N and Vernillet L: Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol 65: 355-363, 2008.
10. Huang X, Li J, Sun R, Cheng Z and Zheng Q: Drug and Statistics Software (DAS), version 2.0. Mathematical Pharmacology Professional Committee of China. Am J Pharm Educ 69: 397-398, 2005.
11. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N and Vernillet L: Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45: 821-841, 2006.